AstraZeneca seeks to halt Apotex's US sales of generic Pulmicort
07 April 2009
Nancy Faigen
AstraZeneca has asked a judge in the US District Court for the District of New Jersey to issue a temporary order that would block
Apotex from selling its version of the branded asthma treatment Pulmicort Respules (budesonide inhalation suspension, BIS) in the US.
Apotex won surprise clearance...
Please Login to read the full article.
07 April 2009
Nancy Faigen
Apotex won surprise clearance...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
- AstraZeneca 'disappointed but confident' over Nexium patent decision in Europe
- Pfizer settles with Teva and Actavis, the last act in Neurontin’s 11-year patent fight
- US Capitol Capsule: Health reform extends Medicare solvency, but programme to go bust by 2024
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
